{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:24:33Z","timestamp":1791462273455,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ygyno.2022.10.020","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T08:44:58Z","timestamp":1667292298000},"page":"164-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma"],"prefix":"10.1016","volume":"169","author":[{"given":"Sarah A.","family":"Ackroyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Arguello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Mahdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"ElNaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krivak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie Galvan","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubilee","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mantia-Smaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2022.10.020_bb0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2012.04.021","article-title":"Clear cell carcinoma of the ovary: a review of the literature","volume":"126","author":"del Carmen","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.10.020_bb0010","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2008.05.025","article-title":"Prognostic implication of endometriosis in clear cell carcinoma of the ovary","volume":"110","author":"Orezzoli","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.10.020_bb0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","article-title":"Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers","volume":"109","author":"Chan","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2022.10.020_bb0020","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study","volume":"25","author":"Winter","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.10.020_bb0025","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1006\/gyno.1996.0065","article-title":"Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease","volume":"60","author":"Goff","year":"1996","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.020_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00004347-199501000-00006","article-title":"Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival","volume":"14","author":"Carcangiu","year":"1995","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.10.020_bb0035","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/IGC.0000000000000677","article-title":"Molecular profiling of clear cell ovarian cancers: identifying potential treatment targets for clinical trials","volume":"26","author":"Friedlander","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2022.10.020_bb0040","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/path.5037","article-title":"Clear cell carcinomas of the ovary and kidney: clarity through genomics","volume":"244","author":"Ji","year":"2018","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2016.11.045","article-title":"Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis","volume":"144","author":"Maru","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.10.020_bb0050","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.ygyno.2022.10.020_bb0055","author":"Network"},{"key":"10.1016\/j.ygyno.2022.10.020_bb0060","author":"Network NCC"},{"issue":"9","key":"10.1016\/j.ygyno.2022.10.020_bb0065","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1586\/14737159.2015.1068122","article-title":"BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies","volume":"15","author":"Piva","year":"2015","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"7353","key":"10.1016\/j.ygyno.2022.10.020_bb0070","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/gcc.22507","article-title":"Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing","volume":"57","author":"Shibuya","year":"2018","journal-title":"Genes Chromosom. Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2022.10.020_bb0080","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.ajpath.2017.06.012","article-title":"Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation gene networks","volume":"187","author":"Murakami","year":"2017","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.12.005","article-title":"Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing","volume":"148","author":"Kim","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0090","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2018.09.001","article-title":"Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management","volume":"151","author":"Oda","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0095","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11912-009-0015-5","article-title":"VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy","volume":"11","author":"Cowey","year":"2009","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.020_bb0100","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2018.10.010","article-title":"Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions","volume":"75","author":"Lalani","year":"2019","journal-title":"Eur. Urol."},{"issue":"14","key":"10.1016\/j.ygyno.2022.10.020_bb0105","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0110","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2018.05.018","article-title":"A phase II study of frontline paclitaxel\/carboplatin\/bevacizumab, paclitaxel\/carboplatin\/temsirolimus, or ixabepilone\/carboplatin\/bevacizumab in advanced\/recurrent endometrial cancer","volume":"150","author":"Aghajanian","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ygyno.2018.05.029","article-title":"A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology\/gynecologic oncology group study (GOG-254)","volume":"150","author":"Chan","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2022.10.020_bb0120","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2022.10.020_bb0125","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2003.12.009","article-title":"Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma","volume":"35","author":"Cai","year":"2004","journal-title":"Hum. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.10.020_bb0130","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2022.10.020_bb0135","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of Pembrolizumab in patients with advanced recurrent ovarian Cancer: results from the phase 2 KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0140","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277308","article-title":"Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1\/PD-L1 expression","volume":"6","author":"Howitt","year":"2017","journal-title":"Oncoimmunology."},{"issue":"22","key":"10.1016\/j.ygyno.2022.10.020_bb0145","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of Pembrolizumab in advanced programmed death ligand 1-positive endometrial Cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"34","key":"10.1016\/j.ygyno.2022.10.020_bb0155","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian Cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.020_bb0160","doi-asserted-by":"crossref","first-page":"8990","DOI":"10.1038\/s41598-018-25583-6","article-title":"Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers","volume":"8","author":"Wang","year":"2018","journal-title":"Sci. Rep."},{"issue":"373","key":"10.1016\/j.ygyno.2022.10.020_bb0165","article-title":"Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer","volume":"20","author":"Bi","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ygyno.2019.02.005","article-title":"Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients","volume":"153","author":"Rodriguez-Freixinos","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0175","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ygyno.2017.05.011","article-title":"Identification of molecular targets in vulvar cancers","volume":"146","author":"Palisoul","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.10.020_bb0180","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ygyno.2015.06.034","article-title":"Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma","volume":"138","author":"Jones","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.020_bb0185","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ygyno.2021.08.027","article-title":"Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancer","volume":"163","author":"Somasegar","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.10.020_bb0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na\u00efve study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med."},{"key":"10.1016\/j.ygyno.2022.10.020_bb0195","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-one strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822018972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822018972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:04:34Z","timestamp":1758773074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822018972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"alternative-id":["S0090825822018972"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}